Journal Mobile Options
Table of Contents
Vol. 72, No. 1, 2004
Issue release date: August 2004
Pharmacology 2004;72:51–56
(DOI:10.1159/000078632)

Itch-Scratch Responses Induced by Lysophosphatidic Acid in Mice

Hashimoto T. · Ohata H. · Momose K.
Department of Pharmacology, School of Pharmaceutical Sciences, Showa University, Tokyo, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The present investigation was conducted in order to determine whether lysophosphatidic acid (LPA) induces itch-scratch responses (ISRs) in mice. Intradermal administration of LPA induces ISRs; furthermore, the time course for LPA-induced ISRs was similar to that for histamine-induced responses. Comparative study of the pruritogenic activity revealed that histamine possessed a potent effect characterized by a dose-response relationship; however, prostaglandin D2 failed to induce this response. Pretreatment with ketotifen, a histamine H1 receptor antagonist, and capsaicin inhibited LPA-induced ISRs. Additionally, LPA-induced ISRs were abolished by Y-27632, an inhibitor of Rho-associated protein kinase (ROCK). These findings suggest that LPA-induced ISRs are attributable to histamine- and substance-P-mediated pathways. Moreover, the Rho/ROCK-mediated pathway may be involved.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Watson SP, McConnell RT, Lapetina EG: Decanoyl lysophosphatidic acid induces platelet aggregation through an extracellular action: Evidence against a second messenger role for lysophosphatidic acid. Biochem J 1985;232:61–66.
  2. Bocckino SB, Blackmore PF, Wilson PB, Exton JH: Phosphatidate accumulation in hormone-treated hepatocytes via a phospholipase D mechanism. J Biol Chem 1987;262:15309–15315.
  3. Gerrard JM, Robinson P: Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin. Biochim Biophys Acta 1989;1001:282–285.
  4. Moolenaar WH: Lysophosphatidic acid signalling. Curr Opin Cell Biol 1995;7:203–210.

    External Resources

  5. Rizza C, Leitinger N, Yue J, Fischer DJ, Wang DA, Shih PT, Lee H, Tigyi G, Berliner JA: Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction. Lab Invest 1999;79:1227–1235.
  6. Toews ML, Ustinova EE, Schultz HD: Lysophosphatidic acid enhances contractility of isolated airway smooth muscle. J Appl Physiol 1997;83:1216–1222.
  7. Sakai J, Oike M, Hirakawa M, Ito Y: Theophylline and cAMP inhibit lysophosphatidic acid-induced hyperresponsiveness of bovine tracheal smooth muscle cells. J Physiol 2003;549(Pt 1):171–180.
  8. Hashimoto T, Nakano Y, Ohata H, Momose K: Lysophosphatidic acid enhances airway response to acetylcholine in guinea pigs. Life Sci 2001;70:199–205.
  9. Hashimoto T, Nakano Y, Yamashita M, Fang YI, Ohata H, Momose K: Role of Rho-associated protein kinase and histamine in lysophosphatidic acid-induced airway hyperresponsiveness in guinea pigs. Jpn J Pharmacol 2002;88:256–261.
  10. Hashimoto T, Yamashita M, Ohata H, Momose K: Lysophosphatidic acid enhances in vivo infiltration and activation of guinea pig eosinophils and neutrophils via a Rho/Rho-associated protein kinase-mediated pathway. J Pharmacol Sci 2003;91:8–14.
  11. Sane AC, Mendenhall T, Bass DA: Secretory phospholipase A2 activity is elevated in bronchoalveolar lavage fluid after ovalbumin sensitization of guinea pigs. J Leukoc Biol 1996;60:704–709.
  12. Bowton DL, Seeds MC, Fasano MB, Goldsmith B, Bass DA: Phospholipase A2 and arachidonate increase in bronchoalveolar lavage fluid after inhaled antigen challenge in asthmatics. Am J Respir Crit Care Med 1997;155:421–425.
  13. Lorette G, Vaillant L: Pruritus: Current concepts in pathogenesis and treatment. Drugs 1990;39:218–223.
  14. Bielory L, Goodman PE, Fisher EM: Allergic ocular disease: A review of pathophysiology and clinical presentations. Clin Rev Allergy Immunol 2001;20:183–200.
  15. Cook PR: Seasonal allergic rhinitis. Mo Med 1996;93:247–250.
  16. Kuraishi Y, Nagasawa T, Hayashi K, Satoh M: Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur J Pharmacol 1995;14:229–233.
  17. Woodward DF, Nieves AL, Spada CS, Williams LS, Tuckett RP: Characterization of a behavioral model for peripherally evoked itch suggests platelet-activating factor as a potent pruritogen. J Pharmacol Exp Ther 1995;272:758–765.
  18. Inagaki N, Nakamura N, Nagao M, Kawasaki H, Nagai H: Inhibition of passive cutaneous anaphylaxis-associated scratching behavior by mu-opioid receptor antagonist in ICR mice. Int Arch Allergy Immunol 2000;123:365–368.
  19. Fukuda S, Midoro K, Yamasaki M, Gyoten M, Kawano Y, Fukui H, Ashida Y, Nagaya H: Characteristics of the antihistamine effect of TAK-427, a novel imidazopyridazine derivative. Inflamm Res 2003;52:206–214.
  20. Woodward DF, Nieves AL, Friedlaender MH: Characterization of receptor subtypes involved in prostanoid-induced conjunctival pruritus and their role in mediating allergic conjunctival itching. J Pharmacol Exp Ther 1996;279:137–142.
  21. Renbäck K, Inoue M, Ueda H: Lysophosphatidic acid-induced, pertussis toxin-sensitive nociception through a substance P release from peripheral nerve endings in mice. Neurosci Lett 1999;270:59–61.
  22. Renbäck K, Inoue M, Yoshida A, Nyberg F, Ueda H: Vzg-1/lysophosphatidic acid-receptor involved in peripheral pain transmission. Brain Res Mol Brain Res 2000;75:350–354.
  23. Greaves MW, Wall PD: Pathophysiology of itching. Lancet 1996;348:938–940.
  24. Morris JB, Symanowicz PT, Olsen JE, Thrall RS, Cloutier MM, Hubbard AK: Immediate sensory nerve-mediated respiratory responses to irritants in healthy and allergic airway-diseased mice. J Appl Physiol 2003;94:1563–1571.
  25. Greaves MW, McDonald-Gibson W: Itch: Role of prostaglandins. Br Med J 1973;3:608–609.
  26. Davies MG, Greaves MW: The current status of histamine receptor in human skin: Therapeutic implications. Br J Dermatol 1981;104:601–606.
  27. Hägermark Ö, Hökfelt T, Pernow B: Flare and itch induced by substance P in human skin. J Invest Dermatol 1978;71:233–235.
  28. Erjavec F, Lembeck F, Florjanc-Irman T, Skofitsch G, Donnerer J, Saria A, Holzer P: Release of histamine by substance P. Naunyn Schmiedebergs Arch Pharmacol 1981;317:67–70.
  29. Schmelz M, Zeck S, Raithel M, Rukwied R: Mast cell tryptase in dermal neurogenic inflammation. Clin Exp Allergy 1999;29:695–702.
  30. Andoh T, Kuraishi Y: Inhibitory effects of azelastine on substance P-induced itch-associated response in mice. Eur J Pharmacol 2002;436:235–239.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50